When Mounjaro stops working: understanding a weight-loss plateau

What the trial data say about plateaus during tirzepatide treatment

In SURMOUNT-1, published in the New England Journal of Medicine, participants on the highest tirzepatide dose lost around 20–21% of their body weight over 72 weeks. What those headline figures rarely show is the shape of the curve: the steepest losses came in the first 16 to 24 weeks, after which progress flattened considerably for many participants before eventually continuing. Physiologically, this reflects the body's ability to reduce its resting energy expenditure as weight drops, a counter-regulatory process sometimes called metabolic adaptation. The medicine is still acting on the GIP and GLP-1 receptors, still slowing gastric emptying, still influencing satiety signals. The problem is that a body at a lower weight now needs fewer calories, so the deficit that drove early losses narrows.

That distinction matters. Tirzepatide not working anymore is a different situation from tirzepatide not working yet, the first is a plateau inside an otherwise effective course of treatment, the second is a signal to review dose or technique. Our guide to how Mounjaro works covers the underlying mechanism in more detail if that context is useful.

The most likely reasons your progress has levelled off

Several practical factors can drive a plateau that looks like the medicine failing when it isn't. Injection technique is worth checking first: if the pen has been stored outside the fridge for longer than the Patient Information Leaflet specifies, or if the injection site has not been rotated regularly, absorption can be inconsistent. A common routine error is leaving the pen on a kitchen counter for weeks rather than returning it to the fridge door between doses, small habits, real consequences.

Beyond technique, calorie adaptation is the most frequently overlooked factor. Appetite suppression from tirzepatide is real, but it is not absolute. As the body adjusts over months, hunger signals can recover partially, and food intake can creep upward without the person noticing. Protein intake in particular tends to fall when appetite is suppressed, which can cause muscle loss rather than fat loss and reduce basal metabolic rate further. Reduced physical activity (often because early weight loss brings relief from joint pain, and that urgency to move fades) can also quietly shrink the total daily energy deficit.

Dose level is another variable. Treatment starts at 2.5 mg to allow the digestive system to settle, and therapeutic benefit typically builds through each upward step. If someone has been on the same dose for many months and progress has stalled, a prescriber may consider whether an increase to the next licensed strength is clinically appropriate. That assessment should include evidence of how the current dose has been tolerated and whether weight loss has genuinely plateaued rather than simply slowed. More detail on how timing affects results is covered in our page on how long Mounjaro takes to work.

What a prescriber can actually do about it

A clinical review of a plateau is not a tick-box exercise. A GPhC-registered prescriber will want to understand how long progress has stalled, what the current dose and injection pattern look like, whether storage and technique are correct, and whether any lifestyle factors have shifted. From that review, the options include a dose increase (if not already at the maximum tolerated strength), a reassessment of dietary approach with a focus on protein and fibre adequacy, and a structured review of activity. What a prescriber will not do (and what you should not do independently) is simply push through to a higher dose without that assessment. Every repeat prescription at nume is reviewed individually by a named clinician before it is issued; the same rigour applies to a request driven by a plateau.

If you are weighing up whether a different treatment might suit you better, the free consultation page is the right starting point. For those wondering whether others have navigated the same experience, the community discussion on plateaus covers a range of shared experiences, and our page on what to do if Mounjaro isn't working sets out the clinical decision points in more detail.

When stopping is the wrong answer to a plateau

The evidence from SURMOUNT-1 and related analyses is clear on one point: weight regain after stopping tirzepatide is rapid and substantial. Stopping in response to a plateau (before a prescriber has had the chance to review dose, technique or lifestyle factors) removes the medicine's protective effect at exactly the moment the body is primed to restore the weight it lost. The NHS's patient information on tirzepatide notes that this is a long-term treatment for a chronic condition, not a short course. A plateau should prompt a conversation with your prescriber, not a decision to stop. If you are trying to understand whether what you are experiencing is a true plateau or something else, our page on why Mounjaro may not be working can help you work through the most common explanations before your next clinical review. If the medicine genuinely is not working after a thorough clinical review and an adequate trial at the highest tolerated dose, then stopping or switching is a considered decision made together with a clinician, not a reaction to a difficult month on the scales. Our team's broader thinking on this is available through the tirzepatide not working for weight loss page, and details about who assesses your treatment are on the clinical team profile.